Compare ARWR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | CYTK |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 7.6B |
| IPO Year | 2009 | 2004 |
| Metric | ARWR | CYTK |
|---|---|---|
| Price | $73.24 | $77.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $83.40 | ★ $89.26 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,142,321.00 | $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | N/A | $310.19 |
| P/E Ratio | $353.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.30 | $29.31 |
| 52 Week High | $79.48 | $80.20 |
| Indicator | ARWR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 69.50 |
| Support Level | $60.60 | $58.59 |
| Resistance Level | $76.45 | N/A |
| Average True Range (ATR) | 3.58 | 3.62 |
| MACD | 0.04 | 1.39 |
| Stochastic Oscillator | 40.58 | 84.90 |
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.